このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Oral N-Acetylcysteine on Diabetic Macular Edema

2026年11月3日 更新者:Khadija Ahmed Mhrose Glal

Effect of Oral N-Acetylcysteine on Diabetic Macular Edema in Type 2 Diabetic Patients With Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the leading causes of preventable visual impairment among working-age adults, with diabetic macular edema (DME) representing one of its most important vision-threatening complications. Diabetic macular edema develops when diabetes-associated retinal vascular dysfunction leads to disruption of the blood-retinal barrier (BRB), allowing fluid and plasma components to accumulate within the retinal tissue and impair macular function. The development and persistence of DME involve a complex interplay between vascular, inflammatory, metabolic, and oxidative mechanisms.

Hyperglycemia is a central driver of the molecular abnormalities underlying diabetic retinal injury. Chronic exposure to elevated glucose activates several interrelated pathways, including the polyol, advanced glycation end-products (AGEs), protein kinase C (PKC), and hexosamine pathways. These metabolic disturbances promote the generation of reactive oxygen species (ROS), inflammatory signaling, endothelial dysfunction, and progressive impairment of the retinal neurovascular unit. Together, these processes contribute to damage to endothelial cells, pericytes, Müller cells, and other retinal components, ultimately compromising the integrity of the BRB.

Oxidative stress is therefore considered an important component of the pathophysiology of DR and DME. Excessive ROS production can directly damage cellular structures and can also amplify inflammatory and angiogenic signaling. This may increase the expression of several mediators implicated in retinal vascular dysfunction. The resulting vascular instability and increased permeability facilitate fluid extravasation into the retinal layers and contribute to the development and progression of DME.

Malondialdehyde (MDA), a product of lipid peroxidation, is widely used as a marker of oxidative damage. Increased MDA concentrations have been reported in patients with diabetic retinopathy and have been associated with the presence or severity of retinal disease, supporting the involvement of oxidative stress in diabetic retinal injury. Assessment of MDA may therefore provide a useful systemic indicator of the oxidative component of the disease process.

Angiopoietin-2 (Ang-2), an important regulator of vascular stability, has also been implicated in diabetic retinal vascular dysfunction. Increased Ang-2 can promote endothelial destabilization and enhance vascular permeability, particularly in the presence of inflammatory and VEGF-related signaling. Thus, oxidative stress and angiogenic dysregulation may represent interconnected components of the vascular injury that ultimately leads to BRB disruption and retinal fluid accumulation.

Current management of DME relies predominantly on ophthalmic interventions, with corticosteroids and laser photocoagulation having roles in selected clinical settings. Although these approaches have substantially improved visual and anatomical outcomes, persistent or recurrent edema occurs in a proportion of patients, reflecting the multifactorial nature of DME and the involvement of various pathways.

N-acetylcysteine (NAC) is a thiol-containing compound and a precursor of L-cysteine and reduced glutathione. In addition to its established mucolytic properties, NAC has antioxidant activity through direct scavenging of reactive oxygen species and, importantly, through restoration of intracellular glutathione availability. Its ability to modulate oxidative stress has led to extensive investigation of NAC in a variety of clinical conditions characterized by oxidative and inflammatory injury.

Experimental evidence suggests that attenuation of oxidative stress with NAC may reduce diabetes-related retinal injury and suppress the expression of vascular and inflammatory mediators, including VEGF and intercellular adhesion molecule-1 (ICAM-1). However, the potential clinical relevance of oral NAC in patients with diabetic retinal disease remains insufficiently characterized.

調査の概要

状態

募集

介入・治療

研究の種類

介入

入学 (推定)

50

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年~69年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients with type 2 diabetes mellitus
  • Adults aged >18 and <70 years.
  • Patients of either sex.
  • Patients with center-involving diabetic macular edema (CI-DME) with best-corrected visual acuity of 20/25 or better in the study eye and who are considered eligible for observation without immediate anti-VEGF treatment according to predefined ophthalmological criteria.
  • Clear ocular media allowing good quality OCT macula imaging.

Exclusion Criteria:

  • Presence of ophthalmic diseases other than diabetic retinopathy that may affect macular thickness or visual function (Age-related macular degeneration, epiretinal membrane, vitreomacular traction, significant cataract affecting visual assessment, retinal vein occlusion, uveitis, glaucoma, etc.)
  • Pregnancy or breastfeeding.
  • Current use of systemic antioxidant supplements or antioxidant therapy that could interfere with the study outcomes.
  • History of ocular surgery or laser.
  • Systemic diseases affecting retinal microvasculature other than diabetes (e.g., uncontrolled hypertension, vasculitis).
  • Poor image quality (media opacity, interferes with OCT imaging).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:コントロール
アクティブコンパレータ:NAC group

N-acetylcysteine (NAC) at a total daily dose of 1200 mg, administered as 600 mg twice daily

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Central Subfield Thickness (CST) Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
時間枠:3 months

Central subfield thickness (CST), defined as the retinal thickness within the central 1-mm subfield centered on the fovea, will be measured using spectral-domain optical coherence tomography (SD-OCT; DRI OCT Triton, Topcon, Japan). The change in CST from baseline to the end of the 3-month intervention period will be evaluated.

3 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Serum Malondialdehyde (MDA) Concentration
時間枠:3 months

Serum malondialdehyde (MDA), a biomarker of oxidative stress, will be measured at baseline and at the end of the 3-month intervention period. The change in serum MDA concentration from baseline to 3 months will be assessed.

3 months
Change from Baseline in Serum Angiopoietin-2 (Ang-2) Concentration
時間枠:3 months

Serum angiopoietin-2 (Ang-2), a biomarker of vascular destabilization and angiogenic signaling, will be measured at baseline and at the end of the 3-month intervention period. The change in serum Ang-2 concentration from baseline to 3 months will be assessed.

3 months
Change from Baseline in Best-Corrected Visual Acuity (BCVA) Measured Using a Standardized Tumbling E Chart
時間枠:3 months

Best-corrected visual acuity (BCVA) will be assessed using a standardized Tumbling E chart at a distance of 6 meters with appropriate refractive correction. Visual acuity will be recorded according to the predefined chart scoring system and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. The change in BCVA from baseline to 3 months will be evaluated.

3 months
Number of Participants Requiring Rescue Therapy for Diabetic Macular Edema During the Study Period
時間枠:3 months

The number of participants requiring rescue ophthalmological treatment due to clinically significant visual deterioration or worsening of diabetic macular edema during the 3-month follow-up period will be recorded. Rescue treatments may include anti-VEGF therapy, intravitreal corticosteroids, or laser treatment, according to the treating ophthalmologist's clinical judgment and predefined study criteria.

3 months
Number of Participants Experiencing at Least One Adverse Event
時間枠:3 months

The number of participants experiencing at least one adverse event during the intervention period will be recorded. Adverse events will be monitored through weekly telephone follow-up and mont

3 months
Number of Participants Experiencing at Least One Serious Adverse Event
時間枠:3 months

The number of participants experiencing at least one serious adverse event during the intervention period will be recorded and documented, with appropriate clinical management and assessment of the possible relationship to the study medication.

3 months
Number of Participants Discontinuing Study Medication Due to Adverse Events or Intolerance
時間枠:3 months

The number of participants who discontinue the study medication because of adverse events, intolerance, or safety concerns during the intervention period will be recorded.

3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月28日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2027年10月1日

試験登録日

最初に提出

2026年10月28日

QC基準を満たした最初の提出物

2026年11月3日

最初の投稿 (実際)

2026年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NAC&DME

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する